Table 4.
Effect of selected mitocan combinations on primary AML samples.
| Patient sample | Maximal synergya, mean ± SEM | |||
|---|---|---|---|---|
| IACS/VIN | RT/2-DG | CCCP/DAS | ABT-199/LND | |
| AML 1 | 49.2 ± 18.6 | 54.7 ± 7.8 | 27.4 ± 2.8 | 2.3 ± 0.5 |
| AML 2 | 50.7 ± 3.2 | 73.8 ± 3.7 | 25.0 ± 1.0 | 17.7 ± 1.1 |
| AML 3 | 27.0 ± 6.9 | 50.5 ± 2.6 | 14.8 ± 4.0 | 26.9 ± 1.8 |
| AML 4 | 20.1 ± 9.2 | 79.7 ± 5.6 | 7.1 ± 4.2 | 13.8 ± 11.4 |
| AML 5 | 10.1 | 54.3 | 0 | 47.7 |
| AML 6 | 42.1 ± 2.7 | 81.3 ± 1.0 | 28.6 ± 3.8 | 10.5 ± 3.9 |
| AML 7 | 16.5 ± 8.2 | 81.5 ± 7.7 | 11.2 ± 0.8 | 17.4 ± 4.3 |
| AML 8 | 40.7 ± 5.7 | 57.9 ± 2.2 | 12.9 ± 2.5 | 7.5 ± 7.5 |
| AML 9 | 18.3 ± 4.6 | 78.9 ± 2.4 | 29.2 ± 15.2 | 8.9 ± 2.7 |
| AML 10 | 50.9 | 78.1 | 56.2 | 15.0 |
| AML 11 | 4.6 ± 0.1 | 25.6 ± 3.9 | 33.1 ± 23.0 | 16.2 ± 11.7 |
| AML 12 | 46.5 ± 8.9 | 76.7 ± 6.1 | 17.1 ± 6.9 | 0 ± 0 |
| Average | 31.4 | 66.1 | 21.9 | 15.3 |
a
Based on 1–3 independent biological replicates.